title: Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis.
abstract: Sustained progression on the expanded disability status scale (EDSS) is a common outcome measure of disease progression in clinical studies of MS. Unfortunately, this outcome may not accurately measure long-term and irreversible disease progression. To assess the performance of definitions of sustained progression, patients with relapsing-remitting MS (RRMS) or a clinically isolated syndrome with evidence of lesions on a brain MRI were included in our study. Fifteen definitions of sustained progression using both the EDSS and the functional system (FS) scales were investigated. The impact of both relapses and changes in provider on the probability of maintaining progression was also evaluated. Although the provider scoring the EDSS sometimes changed during followup, the provider had access to previous EDSS scores. Between 15.8% and 42.2% of patients experienced sustained progression based on the definitions using EDSS as the outcome, but nearly 50% of these patients failed to maintain sustained progression for the duration of followup. When FS scales were used, progression was most common on the pyramidal and sensory scales. Unfortunately, progression on specific FS scales failed to be more sensitive to irreversible disability. Relapses or changes in provider did not explain the poor performance of the measures. Short-term changes in the EDSS or FS scores may not be an accurate marker of irreversible change in RRMS.
authors.affiliation: Partners MS Center, Harvard Medical School, Brigham and Women's Hospital, 1 Brookline Place, Brookline, MA 02445, USA ; Biostatistics Center, Massachusetts General Hospital, Boston, MA 02114, USA.
authors.forename: Brian C
authors.initials: BC
authors.lastname: Healy
authors.forename: David
authors.initials: D
authors.lastname: Engler
authors.forename: Bonnie
authors.initials: B
authors.lastname: Glanz
authors.forename: Alexander
authors.initials: A
authors.lastname: Musallam
authors.forename: Tanuja
authors.initials: T
authors.lastname: Chitnis
references.citation: Ann Neurol. 2009 Mar;65(3):239-48
references.pmid: 19334069
references.citation: N Engl J Med. 2006 Mar 2;354(9):911-23
references.pmid: 16510745
references.citation: N Engl J Med. 2008 Oct 23;359(17):1786-801
references.pmid: 18946064
references.citation: Neurology. 2008 Aug 26;71(9):624-31
references.pmid: 18480462
references.citation: Neurology. 1995 Feb;45(2):251-5
references.pmid: 7854521
references.citation: Neurology. 2003 Dec 9;61(11):1528-32
references.pmid: 14663037
references.citation: Brain. 2000 May;123 ( Pt 5):1027-40
references.pmid: 10775547
references.citation: Autoimmun Rev. 2006 Oct;5(8):532-6
references.pmid: 17027888
references.citation: Mult Scler. 2006 Dec;12(6):826-9
references.pmid: 17263014
references.citation: Brain. 1993 Feb;116 ( Pt 1):117-34
references.pmid: 8453453
references.citation: Neurology. 1997 Aug;49(2):358-63
references.pmid: 9270562
references.citation: Ann Neurol. 1994;36 Suppl:S108-12
references.pmid: 8017868
references.citation: Brain. 2006 Mar;129(Pt 3):584-94
references.pmid: 16401620
references.citation: Neurology. 1983 Nov;33(11):1444-52
references.pmid: 6685237
references.citation: Brain. 1989 Feb;112 ( Pt 1):133-46
references.pmid: 2917275
references.citation: Brain. 2010 Jul;133(Pt 7):1914-29
references.pmid: 20534650